Jornay PM for ADHD in Children and Teens With Epilepsy
Looks at Jornay PM for ADHD in children and teens with epilepsy.
Plain-language title generated from the registry record
Registry title: Medication Treatment of ADHD in Pediatric Epilepsy
Key facts
- Where
- Baltimore, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
Source: NCT07594652, who can take part
Where in United States
- Kennedy Krieger InstituteBaltimore, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Trial code
- NCT07594652
- Record updated
- 29 July 2026
- Original description
This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy.Read full original descriptionShow less
Use of JornayPM® to Treat ADHD in Pediatric Epilepsy
This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy.
Inclusion: Inclusion criteria:; Established diagnosis of epilepsy that requires treatment with anti-seizure medication; No episodes of seizure clusters or status epilepticus within 30 days prior to entry into the study; Diagnosis of ADHD with functional impairment; Good general health as determined by medical history and physical examination, including stable vital signs; Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance with treatment.
Exclusion: • Previous allergic or hypersensitivity reactions to stimulant medicines including Jornay PM®; Active substance abuse or dependence within 30 days of enrollment; Epilepsy that is unstable or with seizure frequency that exceeds four events per month, based on an average over the previous three months; DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others; Current use of stimulants to treat ADHD; Serious or unstable medical or neurologic conditions such as HIV, liver or kidney disease, cancer or diabetes; Unstable cardiac illness such as arrythmias or cardiomyopathy; Participation in a previous experimental drug study within 30 days of baseline visit; Estimated IQ<70 as indicated by clinical assessment to the degree that rating scales may be invalid; Insufficient capacity of caregiver or legal guardian to understand and appropriately consent for study procedures.